Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Cardiology Reports
Published in: Current Cardiology Reports 12/2017

01-12-2017 | Cardiovascular Genomics (TL Assimes, Section Editor)

Peripheral Arterial Disease Genetics: Progress to Date and Challenges Ahead

Authors: Nathan Belkin, Scott M. Damrauer

Published in: Current Cardiology Reports | Issue 12/2017

Login to get access

Abstract

Purpose of Review

In this paper, we review the progress made thus far in research related to the genetics of peripheral arterial disease (PAD) by detailing efforts to date in heritability, linkage analyses, and candidate gene studies. We further summarize more contemporary genome-wide association studies (GWAS) and epigenetic studies of PAD. Finally, we review current challenges and future avenues of advanced research in PAD genetics including whole genome sequencing studies.

Recent Findings

Studies have estimated the heritability of PAD to be moderate, though the contribution to this heritability that is independent of traditional cardiovascular risk factors remains unclear. Recent efforts have identified SNPs associated with PAD in GWAS analyses, but these have yet to be replicated in independent studies.

Summary

Much remains to be discovered in the field of PAD genetics. An improved understanding of the genetic foundation for PAD will allow for earlier diagnosis of disease and a more complete pathophysiological understanding of the mechanisms of the disease leading to novel therapeutic interventions. Future avenues for success will likely arise from very large-scale GWAS, whole genome sequencing, and epigenetic studies involving very well-characterized cohorts.
Literature
1.
Fowkes FGR, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013;382(9901):1329–40.PubMedCrossRef
2.
Belch JJF, Topol EJ, Agnelli G, Bertrand M, Califf RM, Clement DL, et al. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med. 2003;163(8):884–92.PubMedCrossRef
3.
Weitz JI, Byrne J, Clagett GP, Farkouh ME, Porter JM, Sackett DL, et al. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation. 1996;94(11):3026–49.PubMedCrossRef
4.
Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286(11):1317–24.PubMedCrossRef
5.
McDermott MM, Greenland P, Liu K, Guralnik JM, Criqui MH, Dolan NC, et al. Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. JAMA. 2001;286(13):1599–606.PubMedCrossRef
6.
McDermott MM, Liu K, Greenland P, Guralnik JM, Criqui MH, Chan C, et al. Functional decline in peripheral arterial disease: associations with the ankle brachial index and leg symptoms. JAMA. 2004;292(4):453–61.PubMedCrossRef
7.
8.
Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326(6):381–6.PubMedCrossRef
9.
Newman AB, Shemanski L, Manolio TA, Cushman M, Mittelmark M, Polak JF, et al. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 1999;19(3):538–45.PubMedCrossRef
10.
Iii ERM. Peripheral arterial disease: identification and implications. Arch Intern Med. 2003;163(19):2306–14.CrossRef
11.
Mahoney EM, Wang K, Cohen DJ, Hirsch AT, Alberts MJ, Eagle K, et al. One-year costs in patients with a history of or at risk for atherothrombosis in the United States. Circ Cardiovasc Qual Outcomes. 2008;1(1):38–45.PubMedCrossRef
12.
Hirsch AT, Hartman L, Town RJ, Virnig BA. National health care costs of peripheral arterial disease in the Medicare population. Vasc Med. 2008;13(3):209–15.PubMedCrossRef
13.
Knowles JW, Assimes TL, Li J, Quertermous T, Cooke JP. Genetic susceptibility to peripheral arterial disease: a dark corner in vascular biology. Arterioscler Thromb Vasc Biol. 2007;27(10):2068–78.PubMedPubMedCentralCrossRef
14.
Weinberg I, Giri J, Calfon MA, Hawkins BM, Weinberg MD, Margey R, et al. Anatomic correlates of supra-normal ankle brachial indices. Catheter Cardiovasc Interv Off J Soc Card Angiogr Interv. 2013;81(6):1025–30.CrossRef
15.
Szuba A, Oka RK, Harada R, Cooke JP. Limb hemodynamics are not predictive of functional capacity in patients with PAD. Vasc Med Lond Engl. 2006;11(3):155–63.CrossRef
16.
Long J, Modrall JG, Parker BJ, Swann A, Welborn MB, Anthony T. Correlation between ankle-brachial index, symptoms, and health-related quality of life in patients with peripheral vascular disease. J Vasc Surg. 2004;39(4):723–7.PubMedCrossRef
17.
18.
•• Kullo IJ, Leeper NJ. The genetic basis of peripheral arterial disease: current knowledge, challenges and future directions. Circ Res. 2015;116(9):1551–60. Review of the state of genetic research in PAD in 2015 with particular focus on prior genetic research and early PAD GWAS efforts. PubMedPubMedCentralCrossRef
19.
20.
Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, et al. Finding the missing heritability of complex diseases. Nature. 2009;461(7265):747.PubMedPubMedCentralCrossRef
21.
• Golledge J, Biros E, Bingley J, Iyer V, Krishna SM. Epigenetics and peripheral artery disease. Curr Atheroscler Rep. 2016;18(4):15. Review of epigenetics’ role in peripheral arterial disease with particular focus in miRNA. PubMedCrossRef
22.
•• Krishna SM, Trollope AF, Golledge J. The relevance of epigenetics to occlusive cerebral and peripheral arterial disease. Clin Sci. 2015;128(9):537–58. Thorough 2015 review of the role of epigenetics in cerebral and peripheral arterial disease.PubMedCrossRef
23.
CARDIoGRAMplusC4D Consortium, Deloukas P, Kanoni S, Willenborg C, Farrall M, Assimes TL, et al. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet. 2013;45(1):25–33.
24.
Kullo IJ, Turner ST, Kardia SLR, Mosley TH, Boerwinkle E, de Andrade M. A genome-wide linkage scan for ankle–brachial index in African American and non-Hispanic white subjects participating in the GENOA study. Atherosclerosis. 2006;187(2):433–8.PubMedCrossRef
25.
Murabito JM, Guo C-Y, Fox CS, D’Agostino RB. Heritability of the ankle-brachial index—the Framingham Offspring study. Am J Epidemiol. 2006;164(10):963–8.PubMedCrossRef
26.
Carmelli D, Fabsitz RR, Swan GE, Reed T, Miller B, Wolf PA. Contribution of genetic and environmental influences to ankle-brachial blood pressure index in the NHLBI Twin Study. National Heart, Lung, and Blood Institute. Am J Epidemiol. 2000;151(5):452–8.PubMedCrossRef
27.
Valentine RJ, Verstraete R, Clagett GP, Cohen JC. Premature cardiovascular disease is common in relatives of patients with premature peripheral atherosclerosis. Arch Intern Med. 2000;160(9):1343–8.PubMedCrossRef
28.
Wahlgren CM, Magnusson PKE. Genetic influences on peripheral arterial disease in a twin population. Arterioscler Thromb Vasc Biol. 2011;31(3):678–82.PubMedCrossRef
29.
Wassel CL, Loomba R, Ix JH, Allison MA, Denenberg JO, Criqui MH. Family history of peripheral artery disease is associated with prevalence and severity of peripheral artery disease: the San Diego Population Study (SDPS). J Am Coll Cardiol. 2011;58(13):1386.PubMedPubMedCentralCrossRef
30.
31.
Chang P, Nead KT, Olin JW, Cooke JP, Leeper NJ. Clinical and socioeconomic factors associated with unrecognized peripheral artery disease. Vasc Med Lond Engl. 2014;19(4):289–96.CrossRef
32.
Kuller L, Fisher L, McClelland R, Fried L, Cushman M, Jackson S, et al. Differences in prevalence of and risk factors for subclinical vascular disease among black and white participants in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 1998;18(2):283–93.PubMedCrossRef
33.
Kullo IJ, Bailey KR, Kardia SLR, Mosley TH, Boerwinkle E, Turner ST. Ethnic differences in peripheral arterial disease in the NHLBI Genetic Epidemiology Network of Arteriopathy (GENOA) study. Vasc Med Lond Engl. 2003;8(4):237–42.CrossRef
34.
Singh S, Bailey KR, Kullo IJ. Ethnic differences in ankle brachial index are present in middle-aged individuals without peripheral arterial disease. Int J Cardiol. 2013;162(3):228.PubMedCrossRef
35.
Ye Z, Ali Z, Klee GG, Mosley TH Jr, Kullo IJ. Associations of candidate biomarkers of vascular disease with the ankle–brachial index and peripheral arterial disease. Am J Hypertens. 2013;26(4):495.PubMedPubMedCentralCrossRef
36.
Velescu A, Clara A, Peñafiel J, Grau M, Degano IR, Martí R, et al. Peripheral arterial disease incidence and associated risk factors in a Mediterranean population-based cohort. The REGICOR Study. Eur J Vasc Endovasc Surg. 2016;51(5):696–705.PubMedCrossRef
37.
Sebastianski M, Makowsky MJ, Dorgan M, Tsuyuki RT. Paradoxically lower prevalence of peripheral arterial disease in South Asians: a systematic review and meta-analysis. Heart Br Card Soc. 2014;100(2):100–5.
38.
Tang H, Peng J, Wang P, Risch NJ. Estimation of individual admixture: analytical and study design considerations. Genet Epidemiol. 2005;28(4):289–301.PubMedCrossRef
39.
Scherer ML, Nalls MA, Pawlikowska L, Ziv E, Mitchell G, Huntsman S, et al. Admixture mapping of ankle-arm index: identification of a candidate locus associated with peripheral arterial disease. J Med Genet. 2010;47(1):1.PubMedCrossRef
40.
Lander E, Kruglyak L. Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. Nat Genet. 1995;11(3):241–7.PubMedCrossRef
41.
Gudmundsson G, Matthiasson SE, Arason H, Johannsson H, Runarsson F, Bjarnason H, et al. Localization of a gene for peripheral arterial occlusive disease to chromosome 1p31. Am J Hum Genet. 2002;70(3):586.PubMedPubMedCentralCrossRef
42.
43.
Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science. 1996;273(5281):1516–7.PubMedCrossRef
44.
Zintzaras E, Zdoukopoulos N. A field synopsis and meta-analysis of genetic association studies in peripheral arterial disease: the CUMAGAS-PAD Database. Am J Epidemiol. 2009;170(1):1–11.PubMedCrossRef
45.
Taute BM, Handschug K, Taute R, Seifert H, Gläser C, Podhaisky H. Angiotensin-converting enzyme gene insertion/deletion polymorphism and peripheral arterial occlusive disease. VASA Z Gefasskrankheiten. 1998;27(3):149–53.
46.
Tseng C-H, Tseng C-P. Lack of association between angiotensin-converting enzyme gene polymorphism and peripheral vascular disease in type 2 diabetic patients in Taiwan. Circ J Off J Jpn Circ Soc. 2002;66(11):1014–8.
47.
Renner W, Pabst E, Paulweber B, Malaimare L, Iglseder B, Wascher TC, et al. The angiotensin-converting-enzyme insertion/deletion polymorphism is not a risk factor for peripheral arterial disease. Atherosclerosis. 2002;165(1):175–8.PubMedCrossRef
48.
Ghilardi G, Biondi ML, Battaglioli L, Zambon A, Guagnellini E, Scorza R. Genetic risk factor characterizes abdominal aortic aneurysm from arterial occlusive disease in human beings: CCR5 delta 32 deletion. J Vasc Surg. 2004;40(5):995–1000.PubMedCrossRef
49.
Gugl A, Renner W, Seinost G, Brodmann M, Pabst E, Wascher TC, et al. Two polymorphisms in the fracalkine receptor CX3CR1 are not associated with peripheral arterial disease. Atherosclerosis. 2003;166(2):339–43.PubMedCrossRef
50.
Renner W, Schallmoser K, Gallippi P, Krauss C, Toplak H, Wascher TC, et al. C242T polymorphism of the p22 phox gene is not associated with peripheral arterial occlusive disease. Atherosclerosis. 2000;152(1):175–9.PubMedCrossRef
51.
Renner W, Köppel H, Brodmann M, Pabst E, Schallmoser K, Toplak H, et al. Factor II G20210A and factor V G1691A gene mutations and peripheral arterial occlusive disease. Thromb Haemost. 2000;83(1):20–2.PubMed
52.
Reny JL, Alhenc-Gelas M, Fontana P, Bissery A, Julia PL, Fiessinger JN, et al. The factor II G20210A gene polymorphism, but not factor V Arg506Gln, is associated with peripheral arterial disease: results of a case-control study. J Thromb Haemost. 2004;2(8):1334–40.PubMedCrossRef
53.
Mueller T, Marschon R, Dieplinger B, Haidinger D, Gegenhuber A, Poelz W, et al. Factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations are not associated with chronic limb ischemia: the Linz Peripheral Arterial Disease (LIPAD) study. J Vasc Surg. 2005;41(5):808–15.PubMedCrossRef
54.
Lee AJ, Fowkes FG, Lowe GD, Connor JM, Rumley A. Fibrinogen, factor VII and PAI-1 genotypes and the risk of coronary and peripheral atherosclerosis: Edinburgh Artery Study. Thromb Haemost. 1999;81(4):553–60.PubMed
55.
Renner W, Brodmann M, Pabst E, Stanger O, Wascher TC, Pilger E. The V34L polymorphism of factor XIII and peripheral arterial disease. Int Angiol J Int Union Angiol. 2002;21(1):53–7.
56.
Smith FB, Connor JM, Lee AJ, Cooke A, Lowe GDO, Rumley A, et al. Relationship of the platelet glycoprotein PlA and fibrinogen T/G+1689 polymorphisms with peripheral arterial disease and ischaemic heart disease. Thromb Res. 2003;112(4):209–16.PubMedCrossRef
57.
Fowkes FG, Connor JM, Smith FB, Wood J, Donnan PT, Lowe GD. Fibrinogen genotype and risk of peripheral atherosclerosis. Lancet Lond Engl. 1992;339(8795):693–6.CrossRef
58.
Delanghe J, Langlois M, Duprez D, De Buyzere M, Clement D. Haptoglobin polymorphism and peripheral arterial occlusive disease. Atherosclerosis. 1999;145(2):287–92.PubMedCrossRef
59.
Köppel H, Krippl P, Gasser R, Wascher TC, Paulweber B, Pilger E, et al. Hemochromatosis gene (HFE) polymorphisms are not associated with peripheral arterial disease. Thromb Haemost. 2004;91(6):1258–9.PubMed
60.
Eller P, Schgoer W, Mueller T, Tancevski I, Wehinger A, Ulmer H, et al. Hepatic lipase polymorphism and increased risk of peripheral arterial disease. J Intern Med. 2005;258(4):344–8.PubMedCrossRef
61.
Gaetani E, Flex A, Pola R, Papaleo P, De Martini D, Pola E, et al. The K469E polymorphism of the ICAM-1 gene is a risk factor for peripheral arterial occlusive disease. Blood Coagul Fibrinolysis Int J Haemost Thromb. 2002;13(6):483–8.CrossRef
62.
Renner W, Brodmann M, Winkler M, Washer TC, Pilger E. The PLA1/A2 polymorphism of platelet glycoprotein IIIa is not associated with peripheral arterial disease. Thromb Haemost. 2001;85(4):745–6.PubMed
63.
Flex A, Gaetani E, Pola R, Santoliquido A, Aloi F, Papaleo P, et al. The −174 G/C polymorphism of the interleukin-6 gene promoter is associated with peripheral artery occlusive disease. Eur J Vasc Endovasc Surg. 2002;24(3):264–8.PubMedCrossRef
64.
Stricker H, Soldati G, Balmelli T, Mombelli G. Homocysteine, vitamins and gene mutations in peripheral arterial disease. Blood Coagul Fibrinolysis Int J Haemost Thromb. 2001;12(6):469–75.CrossRef
65.
Fontana P, Gaussem P, Aiach M, Fiessinger J-N, Emmerich J, Reny J-L. P2Y12 H2 haplotype is associated with peripheral arterial disease: a case-control study. Circulation. 2003;108(24):2971–3.PubMedCrossRef
66.
Monsalve MV, Young R, Jobsis J, Wiseman SA, Dhamu S, Powell JT, et al. DNA polymorphisms of the gene for apolipoprotein B in patients with peripheral arterial disease. Atherosclerosis. 1988;70(1–2):123–9.PubMedCrossRef
67.
Fowkes FG, Lee A, Hau C, Cooke A, Connor J, Lowe GD. Methylene tetrahydrofolate reductase (MTHFR) and nitric oxide synthase (ecNOS) genes and risks of peripheral arterial disease and coronary heart disease: Edinburgh artery study. Atherosclerosis. 2000;150(1):179–85.PubMedCrossRef
68.
Morrison AC, Doris PA, Folsom AR, Nieto FJ, Boerwinkle E. G-protein β3 subunit and α-adducin polymorphisms and risk of subclinical and clinical stroke. Stroke. 2001;32(4):822–9.PubMedCrossRef
69.
Li R, Folsom AR, Sharrett AR, Couper D, Bray M, Tyroler HA. Interaction of the glutathione S-transferase genes and cigarette smoking on risk of lower extremity arterial disease: the Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis. 2001;154(3):729–38.PubMedCrossRef
70.
Vazquez F, Rodger M, Carrier M, Le Gal G, Reny J-L, Sofi F, et al. Prothrombin G20210A mutation and lower extremity peripheral arterial disease: a systematic review and meta-analysis. Eur J Vasc Endovasc Surg. 2015;50(2):232–40.PubMedCrossRef
71.
Thorgeirsson TE, Steinberg S, Reginsson GW, Bjornsdottir G, Rafnar T, Jonsdottir I, et al. A rare missense mutation in CHRNA4 associates with smoking behavior and its consequences. Mol Psychiatry. 2016;21(5):594–600.PubMedPubMedCentralCrossRef
72.
Kullo IJ, Greene MT, Boerwinkle E, Chu J, Turner ST, Kardia SLR. Association of polymorphisms in NOS3 with the ankle-brachial index in hypertensive adults. Atherosclerosis. 2008;196(2):905.PubMedCrossRef
73.
74.
Signorelli SS, Barresi V, Musso N, Anzaldi M, Croce E, Fiore V, et al. Polymorphisms of steroid 5-alpha-reductase type I (SRD5A1) gene are associated to peripheral arterial disease. J Endocrinol Investig. 2008;31(12):1092–7.CrossRef
75.
Biscetti F, Porreca CF, Bertucci F, Straface G, Santoliquido A, Tondi P, et al. TNFRSF11B gene polymorphisms increased risk of peripheral arterial occlusive disease and critical limb ischemia in patients with type 2 diabetes. Acta Diabetol. 2014;51(6):1025–32.PubMedCrossRef
76.
Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst. 2004;96(6):434–42.PubMedCrossRef
77.
Wassel CL, Lamina C, Nambi V, Coassin S, Mukamal KJ, Ganesh SK, et al. Genetic determinants of the ankle-brachial index: a meta-analysis of a cardiovascular candidate gene 50K SNP panel in the candidate gene association resource (CARe) consortium. Atherosclerosis. 2012;222(1):138.PubMedPubMedCentralCrossRef
78.
Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 2010;466(7307):707–13.PubMedPubMedCentralCrossRef
79.
Musunuru K, Strong A, Frank-Kamenetsky M, Lee NE, Ahfeldt T, Sachs KV, et al. From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature. 2010;466(7307):714–9.PubMedPubMedCentralCrossRef
80.
Global Lipids Genetics Consortium, Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, et al. Discovery and refinement of loci associated with lipid levels. Nat Genet. 2013;45(11):1274–83.CrossRef
81.
Nejentsev S, Walker N, Riches D, Egholm M, Todd JA. Rare variants of IFIH1, a gene implicated in antiviral responses, protect against type 1 diabetes. Science. 2009;324(5925):387–9.PubMedPubMedCentralCrossRef
82.
Steinthorsdottir V, Thorleifsson G, Sulem P, Helgason H, Grarup N, Sigurdsson A, et al. Identification of low-frequency and rare sequence variants associated with elevated or reduced risk of type 2 diabetes. Nat Genet. 2014;46(3):294–8.PubMedCrossRef
83.
Gaulton KJ, Ferreira T, Lee Y, Raimondo A, Mägi R, Reschen ME, et al. Genetic fine mapping and genomic annotation defines causal mechanisms at type 2 diabetes susceptibility loci. Nat Genet. 2015;47(12):1415–25.PubMedPubMedCentralCrossRef
84.
McPherson R, Pertsemlidis A, Kavaslar N, Stewart A, Roberts R, Cox DR, et al. A common allele on chromosome 9 associated with coronary heart disease. Science. 2007;316(5830):1488–91.PubMedPubMedCentralCrossRef
85.
Harismendy O, Notani D, Song X, Rahim NG, Tanasa B, Heintzman N, et al. 9p21 DNA variants associated with coronary artery disease impair interferon-γ signalling response. Nature. 2011;470(7333):264–8.PubMedPubMedCentralCrossRef
86.
87.
Helgadottir A, Thorleifsson G, Magnusson KP, Grétarsdottir S, Steinthorsdottir V, Manolescu A, et al. The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet. 2008;40(2):217–24.PubMedCrossRef
88.
Cluett C, McDermott MM, Guralnik J, Ferrucci L, Bandinelli S, Miljkovic I, et al. The 9p21 myocardial infarction risk allele increases risk of peripheral artery disease in older people: Cluett—9p21 alleles and peripheral artery disease. Circ Cardiovasc Genet. 2009;2(4):347.PubMedPubMedCentralCrossRef
89.
Thorgeirsson TE, Geller F, Sulem P, Rafnar T, Wiste A, Magnusson KP, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature. 2008;452(7187):638.PubMedPubMedCentralCrossRef
90.
Gretarsdottir S, Baas AF, Thorleifsson G, Holm H, den Heijer M, de Vries J-PPM, et al. Genome-wide association study identifies a sequence variant within the DAB2IP gene conferring susceptibility to abdominal aortic aneurysm. Nat Genet. 2010;42(8):692.PubMedPubMedCentralCrossRef
91.
•• Shi Z-F, Fang Q-B, Limu S, Jiareke T, Ge X-H. Association between three SNPs and thromboangiitis obliterans in Xinjiang Uyghur population. Genet Test Mol Biomarkers. 2016;20(2):55. GWAS performed on thromboangiitis obliterans patients in 2016.PubMedPubMedCentralCrossRef
92.
Małecki R, Zdrojowy K, Adamiec R. Thromboangiitis obliterans in the 21st century—a new face of disease. Atherosclerosis. 2009;206(2):328–34.PubMedCrossRef
93.
Lett RLM, Wang W, O’Connor TP. Semaphorin 5B is a novel inhibitory cue for corticofugal axons. Cereb Cortex N Y N. 2009;19(6):1408–21.CrossRef
94.
Adams RH, Betz H, Püschel AW. A novel class of murine semaphorins with homology to thrombospondin is differentially expressed during early embryogenesis. Mech Dev. 1996;57(1):33–45.PubMedCrossRef
95.
Koriyama H, Nakagami H, Katsuya T, Sugimoto K, Yamashita H, Takami Y, et al. Identification of evidence suggestive of an association with peripheral arterial disease at the OSBPL10 locus by genome-wide investigation in the Japanese population. J Atheroscler Thromb. 2010;17(10):1054–62.PubMedCrossRef
96.
Perttilä J, Merikanto K, Naukkarinen J, Surakka I, Martin NW, Tanhuanpää K, et al. OSBPL10, a novel candidate gene for high triglyceride trait in dyslipidemic Finnish subjects, regulates cellular lipid metabolism. J Mol Med Berl Ger. 2009;87(8):825–35.CrossRef
97.
•• Matsukura M, Ozaki K, Takahashi A, Onouchi Y, Morizono T, Komai H, et al. Genome-wide association study of peripheral arterial disease in a Japanese population. PLoS One. 2015;10(10):e0139262. Recent published PAD GWAS with a total of 3,164 cases. PubMedPubMedCentralCrossRef
98.
99.
Chung KM, Cha S-S, Jang SK. A novel function of karyopherin beta3 associated with apolipoprotein A-I secretion. Mol Cells. 2008;26(3):291–8.PubMed
100.
Yanagisawa M, Kurihara H, Kimura S, Goto K, Masaki T. A novel peptide vasoconstrictor, endothelin, is produced by vascular endothelium and modulates smooth muscle Ca2+ channels. J Hypertens Suppl. 1988;6(4):S188–91.PubMedCrossRef
101.
Murabito JM, White CC, Kavousi M, Sun YV, Feitosa MF, Nambi V, et al. Association between chromosome 9p21 variants and the ankle-brachial index identified by a meta-analysis of 21 genome-wide association studies. Circ Cardiovasc Genet. 2012;5(1):100–12.PubMedCrossRef
102.
Panagiotou OA, Ioannidis JPA, Genome-Wide Significance Project. What should the genome-wide significance threshold be? Empirical replication of borderline genetic associations. Int J Epidemiol. 2012;41(1):273–86.PubMedCrossRef
103.
McCarty CA, Chisholm RL, Chute CG, Kullo IJ, Jarvik GP, Larson EB, et al. The eMERGE Network: a consortium of biorepositories linked to electronic medical records data for conducting genomic studies. BMC Med Genet. 2011;4:13.
104.
Kho AN, Pacheco JA, Peissig PL, Rasmussen L, Newton KM, Weston N, et al. Electronic medical records for genetic research: results of the eMERGE consortium. Sci Transl Med. 2011;3(79):79re1.PubMedPubMedCentralCrossRef
105.
•• Kullo IJ, Shameer K, Jouni H, Lesnick TG, Pathak J, Chute CG, et al. The ATXN2-SH2B3 locus is associated with peripheral arterial disease: an electronic medical record-based genome-wide association study. Front Genet. 2014;5:166. An electronic health record-based GWAS analysis from 2014. PubMedPubMedCentral
106.
Devallière J, Charreau B. The adaptor Lnk (SH2B3): an emerging regulator in vascular cells and a link between immune and inflammatory signaling. Biochem Pharmacol. 2011;82(10):1391–402.PubMedCrossRef
107.
Devallière J, Chatelais M, Fitau J, Gérard N, Hulin P, Velazquez L, et al. LNK (SH2B3) is a key regulator of integrin signaling in endothelial cells and targets α-parvin to control cell adhesion and migration. FASEB J. 2012;26(6):2592–606.PubMedPubMedCentralCrossRef
108.
Abrantes P, Rosa A, Francisco V, Sousa I, Xavier JM, Oliveira SA. Mitochondrial genome association study with peripheral arterial disease and venous thromboembolism. Atherosclerosis. 2016;252:97–105.PubMedCrossRef
109.
Li L, Xie J, Zhang M, Wang S. Homocysteine harasses the imprinting expression of IGF2 and H19 by demethylation of differentially methylated region between IGF2/H19 genes. Acta Biochim Biophys Sin. 2009;41(6):464–71.PubMedCrossRef
110.
Montes de Oca A, Madueño JA, Martinez-Moreno JM, Guerrero F, Muñoz-Castañeda J, Rodriguez-Ortiz ME, et al. High-phosphate-induced calcification is related to SM22α promoter methylation in vascular smooth muscle cells. J Bone Miner Res Off J Am Soc Bone Miner Res. 2010;25(9):1996–2005.CrossRef
111.
Dunn J, Qiu H, Kim S, Jjingo D, Hoffman R, Kim CW, et al. Flow-dependent epigenetic DNA methylation regulates endothelial gene expression and atherosclerosis. J Clin Invest. 2014;124(7):3187–99.PubMedPubMedCentralCrossRef
112.
Jiang Y-Z, Jiménez JM, Ou K, McCormick ME, Zhang L-D, Davies PF. Hemodynamic disturbed flow induces differential DNA methylation of endothelial Kruppel-like Factor 4 promoter in vitro and in vivo. Circ Res. 2014;115(1):32–43.PubMedPubMedCentralCrossRef
113.
Hastings NE, Simmers MB, McDonald OG, Wamhoff BR, Blackman BR. Atherosclerosis-prone hemodynamics differentially regulates endothelial and smooth muscle cell phenotypes and promotes pro-inflammatory priming. Am J Physiol Cell Physiol. 2007;293(6):C1824–33.PubMedCrossRef
114.
Siuda D, Zechner U, El Hajj N, Prawitt D, Langer D, Xia N, et al. Transcriptional regulation of Nox4 by histone deacetylases in human endothelial cells. Basic Res Cardiol. 2012;107(5):283.PubMedCrossRef
115.
Kumar A, Kumar S, Vikram A, Hoffman TA, Naqvi A, Lewarchik CM, et al. Histone and DNA methylation-mediated epigenetic downregulation of endothelial Kruppel-like factor 2 by low-density lipoprotein cholesterol. Arterioscler Thromb Vasc Biol. 2013;33(8):1936–42.PubMedCrossRef
116.
Fan J, Alsarraf O, Dahrouj M, Platt KA, Chou CJ, Rice DS, et al. Inhibition of HDAC2 protects the retina from ischemic injury. Invest Ophthalmol Vis Sci. 2013;54(6):4072–80.PubMedPubMedCentralCrossRef
117.
Wellmann S, Bettkober M, Zelmer A, Seeger K, Faigle M, Eltzschig HK, et al. Hypoxia upregulates the histone demethylase JMJD1A via HIF-1. Biochem Biophys Res Commun. 2008;372(4):892–7.PubMedCrossRef
118.
119.
Saco TV, Parthasarathy PT, Cho Y, Lockey RF, Kolliputi N. Role of epigenetics in pulmonary hypertension. Am J Physiol Cell Physiol. 2014;306(12):C1101–5.PubMedPubMedCentralCrossRef
120.
Chen W, Bacanamwo M, Harrison DG. Activation of p300 histone acetyltransferase activity is an early endothelial response to laminar shear stress and is essential for stimulation of endothelial nitric-oxide synthase mRNA transcription. J Biol Chem. 2008;283(24):16293–8.PubMedPubMedCentralCrossRef
121.
Harris TA, Yamakuchi M, Ferlito M, Mendell JT, Lowenstein CJ. MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc Natl Acad Sci U S A. 2008;105(5):1516–21.PubMedPubMedCentralCrossRef
122.
Zhu N, Zhang D, Chen S, Liu X, Lin L, Huang X, et al. Endothelial enriched microRNAs regulate angiotensin II-induced endothelial inflammation and migration. Atherosclerosis. 2011;215(2):286–93.PubMedCrossRef
123.
Kuehbacher A, Urbich C, Zeiher AM, Dimmeler S. Role of Dicer and Drosha for endothelial microRNA expression and angiogenesis. Circ Res. 2007;101(1):59–68.PubMedCrossRef
124.
Fasanaro P, D’Alessandra Y, Di Stefano V, Melchionna R, Romani S, Pompilio G, et al. MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J Biol Chem. 2008;283(23):15878–83.PubMedPubMedCentralCrossRef
125.
Chen K-C, Wang Y-S, C-Y H, Chang W-C, Liao Y-C, Dai C-Y, et al. OxLDL up-regulates microRNA-29b, leading to epigenetic modifications of MMP-2/MMP-9 genes: a novel mechanism for cardiovascular diseases. FASEB J. 2011;25(5):1718–28.PubMedCrossRef
126.
Sun X, Icli B, Wara AK, Belkin N, He S, Kobzik L, et al. MicroRNA-181b regulates NF-κB-mediated vascular inflammation. J Clin Invest. 2012;122(6):1973–90.PubMedPubMedCentral
127.
Sun X, Belkin N, Feinberg MW. Endothelial microRNAs and atherosclerosis. Curr Atheroscler Rep. 2013;15(12):372.PubMedCrossRef
128.
Sun X, He S, Wara AKM, Icli B, Shvartz E, Tesmenitsky Y, et al. Systemic delivery of microRNA-181b inhibits nuclear factor-κB activation, vascular inflammation, and atherosclerosis in apolipoprotein E-deficient mice. Circ Res. 2014;114(1):32–40.PubMedCrossRef
129.
Sun X, Lin J, Zhang Y, Kang S, Belkin N, Wara AK, et al. MicroRNA-181b improves glucose homeostasis and insulin sensitivity by regulating endothelial function in white adipose tissue. Circ Res. 2016;118(5):810–21.PubMedPubMedCentralCrossRef
130.
Kovacs B, Lumayag S, Cowan C, Xu S. microRNAs in early diabetic retinopathy in streptozotocin-induced diabetic rats. Invest Ophthalmol Vis Sci. 2011;52(7):4402–9.PubMedCrossRef
131.
Noh H, Oh EY, Seo JY, Yu MR, Kim YO, Ha H, et al. Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta1-induced renal injury. Am J Physiol Renal Physiol. 2009;297(3):F729–39.PubMedCrossRef
132.
Zhang D, Yu Z, Cruz P, Kong Q, Li S, Kone BC. Epigenetics and the control of epithelial sodium channel expression in collecting duct. Kidney Int. 2009;75(3):260–7.PubMedCrossRef
133.
Lee ME, Wang H. Homocysteine and hypomethylation. A novel link to vascular disease. Trends Cardiovasc Med. 1999;9(1–2):49–54.PubMedCrossRef
134.
Yan T-T, Li Q, Zhang X-H, Wu W-K, Sun J, Li L, et al. Homocysteine impaired endothelial function through compromised vascular endothelial growth factor/Akt/endothelial nitric oxide synthase signalling. Clin Exp Pharmacol Physiol. 2010;37(11):1071–7.PubMedCrossRef
135.
Ying AK, Hassanain HH, Roos CM, Smiraglia DJ, Issa JJ, Michler RE, et al. Methylation of the estrogen receptor-alpha gene promoter is selectively increased in proliferating human aortic smooth muscle cells. Cardiovasc Res. 2000;46(1):172–9.PubMedCrossRef
136.
Bhaumik D, Scott GK, Schokrpur S, Patil CK, Orjalo AV, Rodier F, et al. MicroRNAs miR-146a/b negatively modulate the senescence-associated inflammatory mediators IL-6 and IL-8. Aging. 2009;1(4):402–11.PubMedPubMedCentralCrossRef
137.
Magenta A, Cencioni C, Fasanaro P, Zaccagnini G, Greco S, Sarra-Ferraris G, et al. miR-200c is upregulated by oxidative stress and induces endothelial cell apoptosis and senescence via ZEB1 inhibition. Cell Death Differ. 2011;18(10):1628–39.PubMedPubMedCentralCrossRef
138.
Vasa-Nicotera M, Chen H, Tucci P, Yang AL, Saintigny G, Menghini R, et al. miR-146a is modulated in human endothelial cell with aging. Atherosclerosis. 2011;217(2):326–30.PubMedCrossRef
139.
Breitling LP, Yang R, Korn B, Burwinkel B, Brenner H. Tobacco-smoking-related differential DNA methylation: 27K discovery and replication. Am J Hum Genet. 2011;88(4):450–7.PubMedPubMedCentralCrossRef
140.
Zöchbauer-Müller S, Lam S, Toyooka S, Virmani AK, Toyooka KO, Seidl S, et al. Aberrant methylation of multiple genes in the upper aerodigestive tract epithelium of heavy smokers. Int J Cancer. 2003;107(4):612–6.PubMedCrossRef
141.
Yanagawa N, Tamura G, Oizumi H, Endoh M, Sadahiro M, Motoyama T. Inverse correlation between EGFR mutation and FHIT, RASSF1A and RUNX3 methylation in lung adenocarcinoma: relation with smoking status. Anticancer Res. 2011;31(4):1211–4.PubMed
142.
Ostrow KL, Hoque MO, Loyo M, Brait M, Greenberg A, Siegfried JM, et al. Molecular analysis of plasma DNA for the early detection of lung cancer by quantitative methylation-specific PCR. Clin Cancer Res Off J Am Assoc Cancer Res. 2010;16(13):3463–72.CrossRef
143.
Breton CV, Byun H-M, Wenten M, Pan F, Yang A, Gilliland FD. Prenatal tobacco smoke exposure affects global and gene-specific DNA methylation. Am J Respir Crit Care Med. 2009;180(5):462–7.PubMedPubMedCentralCrossRef
144.
Sharma P, Kumar J, Garg G, Kumar A, Patowary A, Karthikeyan G, et al. Detection of altered global DNA methylation in coronary artery disease patients. DNA Cell Biol. 2008;27(7):357–65.PubMedCrossRef
145.
Pearce MS, McConnell JC, Potter C, Barrett LM, Parker L, Mathers JC, et al. Global LINE-1 DNA methylation is associated with blood glycaemic and lipid profiles. Int J Epidemiol. 2012;41(1):210–7.PubMedPubMedCentralCrossRef
146.
Ling C, Rönn T. Epigenetic adaptation to regular exercise in humans. Drug Discov Today. 2014;19(7):1015–8.PubMedCrossRef
147.
White AJ, Sandler DP, Bolick SCE, Xu Z, Taylor JA, DeRoo LA. Recreational and household physical activity at different time points and DNA global methylation. Eur J Cancer Oxf Engl. 2013;49(9):2199–206.CrossRef
148.
149.
Rasmussen HB, Timm S, Wang AG, Søeby K, Lublin H, Fenger M, et al. Association between the CCR5 32-bp deletion allele and late onset of schizophrenia. Am J Psychiatry. 2006;163(3):507–11.PubMedCrossRef
150.
Davidsen PK, Gallagher IJ, Hartman JW, Tarnopolsky MA, Dela F, Helge JW, et al. High responders to resistance exercise training demonstrate differential regulation of skeletal muscle microRNA expression. J Appl Physiol Bethesda. 2011;110(2):309–17.CrossRef
151.
Li T, Cao H, Zhuang J, Wan J, Guan M, Yu B, et al. Identification of miR-130a, miR-27b and miR-210 as serum biomarkers for atherosclerosis obliterans. Clin Chim Acta Int J Clin Chem. 2011;412(1–2):66–70.CrossRef
152.
•• Stather PW, Sylvius N, Wild JB, Choke E, Sayers RD, Bown MJ. Differential microRNA expression profiles in peripheral arterial disease. Circ Cardiovasc Genet. 2013;6(5):490–7. Review of miRNA rose in abdominal aortic aneurysms and peripheral arterial disease from 2015. PubMedCrossRef
153.
Stather PW, Sylvius N, Sidloff DA, Dattani N, Verissimo A, Wild JB, et al. Identification of microRNAs associated with abdominal aortic aneurysms and peripheral arterial disease. Br J Surg. 2015;102(7):755–66.PubMedCrossRef
154.
Zhang Y, Wang Z, Gemeinhart RA. Progress in microRNA delivery. J Control Release Off J Control Release Soc. 2013;172(3):962–74.CrossRef
155.
156.
Dewey FE, Murray MF, Overton JD, Habegger L, Leader JB, Fetterolf SN, et al. Distribution and clinical impact of functional variants in 50,726 whole-exome sequences from the DiscovEHR study. Science. 2016;354(6319):aaf6814.PubMedCrossRef
157.
Gaziano JM, Concato J, Brophy M, Fiore L, Pyarajan S, Breeling J, et al. Million Veteran Program: a mega-biobank to study genetic influences on health and disease. J Clin Epidemiol. 2016;70:214–23.PubMedCrossRef
158.
159.
160.
Biesecker LG, Green RC. Diagnostic clinical genome and exome sequencing. N Engl J Med. 2014;371(12):1170.PubMedCrossRef
161.
Biesecker LG, Green RC. Diagnostic clinical genome and exome sequencing. N Engl J Med. 2014;370(25):2418–25.PubMedCrossRef
162.
Kiezun A, Garimella K, Do R, Stitziel NO, Neale BM, McLaren PJ, et al. Exome sequencing and the genetic basis of complex traits. Nat Genet. 2012;44(6):623–30.PubMedPubMedCentralCrossRef
163.
164.
165.
•• Abramowitz Y, Roth A, Keren G, Isakov O, Shomron N, Laitman Y, et al. Whole-exome sequencing in individuals with multiple cardiovascular risk factors and normal coronary arteries. Coron Artery Dis. 2016;27(4):257–66. Whole exome sequencing analysis performed investigating variants protective of coronary artery disease. PubMedCrossRef
166.
Lasota AN, Overvad K, Eriksen HH, Tjønneland A, Schmidt EB, Grønholdt M-LM. Validity of peripheral arterial disease diagnoses in the Danish National Patient Registry. Eur J Vasc Endovasc Surg Off J Eur Soc Vasc Surg. 2017;53(5):679–85.CrossRef
Metadata
Title
Peripheral Arterial Disease Genetics: Progress to Date and Challenges Ahead
Authors
Nathan Belkin
Scott M. Damrauer
Publication date
01-12-2017
Publisher
Springer US
Published in
Current Cardiology Reports / Issue 12/2017
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-017-0939-6

Other articles of this Issue 12/2017

Current Cardiology Reports 12/2017 Go to the issue

Hypertension (DS Geller and DL Cohen, Section Editors)

Hypertension in African Americans

Heart Failure (HJ Eisen, Section Editor)

Evaluation of a Heart Transplant Candidate

Stroke (JF Meschia, Section Editor)

Clinical Management of Cavernous Malformations

Echocardiography (JM Gardin and AH Waller, Section Editors)

Echocardiography in Infective Endocarditis: State of the Art

Stroke (JF Meschia, Section Editor)

Carotid Angioplasty and Stenting and Embolic Protection

Echocardiography (JM Gardin and AH Waller, Section Editors)

Stress Echocardiography in Stable Coronary Artery Disease

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits